The Effect of Different Physical Activity Strategy on Cognitive Efficiency and Mental Fatigue Resistance

NCT07130825, Not applicable, Recruiting, Lithuanian Sports University

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Field	Value	Source
Title	The Effect of Different Physical Activity Strategy on Cognitive Efficiency and Mental Fatigue Resistance	ClinicalTrials.gov
NCT number	NCT07130825	ClinicalTrials.gov
Status	Recruiting	ClinicalTrials.gov
Phases	Not applicable	ClinicalTrials.gov
Enrollment	60 participants, estimated	ClinicalTrials.gov
Lead sponsor	Lithuanian Sports University	ClinicalTrials.gov
Conditions	Healthy Adults	ClinicalTrials.gov
Interventions	8 hours simulated mental workday, Moderate intensity aerobic activity, Combined work model	ClinicalTrials.gov
First posted	2025-08-19	ClinicalTrials.gov
Last updated	2025-08-19	ClinicalTrials.gov

Registered outcomes 21

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description	Source
Primary	Body mass and body composition (kg)	2 times in the mornings (day 1 and day 2) of each 3 conditions.	Body mass and composition (in kilograms) will be evaluated using Tanita Body Composition Analyzer (Japan).	ClinicalTrials.gov
Primary	Height (m)	2 times in the mornings (day 1 and day 2) of each 3 conditions.	Height (in meters) will be measured using a Harpenden anthropometer set (Holtain Ltd, UK).	ClinicalTrials.gov
Primary	Brain hemodynamic response	Before, immediately after the simulated mental workday, 3 hours after the simulated mental workday, and 12 hours recovery after a simulated mental workday in 3 conditions.	To measure and evaluate hemodynamic response, a functional near-infrared (fNIRS) device NIRx NIRS Sport2 (Medical Technologies LLC-NIR-Scout, USA) with 8 near-infrared (NIR) radiation sources and 7 photodetectors will be used. The photodetectors record the relative changes in oxygen and oxygenated hemoglobin at 7.81 Hz for both wavelengths. The probes are placed at the manufacturer's specified locations to capture the hemodynamic response of the prefrontal cortex. Live recording will be monitored for 6 minutes.	ClinicalTrials.gov
Primary	Cognitive performance	Day 1 in 3 different conditions, in 1 condition 8 times for 45 minutes.	Automated Neuropsychological Assessment Metrics Test Set (ANAM4, version 4; Vista Life Science, Norman, OK, USA). 11 tests will be selected, reflecting the three main cognitive functions - memory, attention and executive function. 11 tests: Procedural RT, Memory search, Spatial processing simultaneous, Matching grids, Matching to sample, Stroop colour word test, Code substitution-learning and Code substitution-delayed, Running memory continuous performance, Continous performance test - traditional. To assess cognitive performance, during a simulated 8-hour mental work day, the subjects will complete a set of cognitive tests 8 times (1 session approximately 45 minutes), after each session there will be a break of approximately 10 minutes. Participants were familiarized with the test battery twice before the experiments.	ClinicalTrials.gov
Primary	Blood pressure (mmHg)	11 times during 1 condition (total 33 times).	Systolic and diastolic blood pressure (in mmHg) will be measured using a blood pressure monitor (Biolight, Patient Monitor S10, Guangdong Biolight Meditech Co, Hamburg, Germany).	ClinicalTrials.gov
Primary	Heart rate and heart rate variability (ms)	During 1 condition rest measurements in the morning, during brain hemodynamic response (3 times during 1 condition), during every session of 8 hours simultaneous mental work day, total 3 conditions.	Heart rate (HR) will be recorded using a heart rate monitor (Polar H10, Kempele, Finland) with an electrode strap around the chest throughout the study. 5-min RR interval file will then be analyzed using Kubios HR Variability Analysis Software 2.0 (Biomedical Signal and Medical Image Analysis Group, Department of Applied Physics, University of Kuopio, Kuopio, Finland).	ClinicalTrials.gov
Primary	Glucose level (mmol/l)	9 times during 1 condition (total 27 times).	Glucose level will be measured from capillary blood using Akray glucose analyzer (CONTOUR®PLUS ELITE; Basel, Switzerland). Capillary blood samples will be taken by a qualified medical professional (general practice nurse) at the LSU Institute of Sports Science and Innovation laboratory.	ClinicalTrials.gov
Primary	Ketones level (mmol/L)	9 times during 1 condition (total 27 times).	Ketones level will be measured from capillary blood using a ketone analyzer (The On Call® GK Dual; San Diego, CA; USA). Capillary blood samples will be taken by a qualified medical professional (general practice nurse) at the LSU Institute of Sports Science and Innovation laboratory.	ClinicalTrials.gov
Primary	Lactate level (mmol/L)	9 times during 1 condition (total 27 times).	Lactate levels will be measured using a lactate analyzer (Lactatte Pro 2, Arkray, Koji Konan-cho, Koka-shi, Japan). Capillary blood samples will be taken by a qualified medical professional (general practice nurse) at the LSU Institute of Sports Science and Innovation laboratory.	ClinicalTrials.gov
Primary	Salivary cortisol concentration (µg/dl)	11 times during 1 condition (total 33 times).	The saliva samples will be collected to measure cortisol level (in µg/dl) using an ELISA kits and a Spark multimode microplate reader (Tecan, Austria).	ClinicalTrials.gov
Primary	Salivary testosterone concentration (µg/dl)	11 times during 1 condition (total 33 times).	The saliva samples will be collected to measure cortisol level (in µg/dl) using an ELISA kits and a Spark multimode microplate reader (Tecan, Austria).	ClinicalTrials.gov
Primary	Salivary female sex hormones concentration (pgmol/L)	11 times during 1 condition (total 33 times).	The saliva samples will be collected to measure cortisol level (in µg/dl) using an ELISA kits and a Spark multimode microplate reader (Tecan, Austria).	ClinicalTrials.gov
Primary	Biochemical urine analysis	2 times during 1 condition (total 6 times).	The urine sample will be analyzed in the laboratory using a urine analyzer (PocketChem UA, PU-4010, Arkray, Koji, Konan-cho, Koka-shi, Japan). The analyzer will determine the concentrations of ketones.	ClinicalTrials.gov
Primary	Pupil diameter (mm)	Before and 3 times during simulated 8 hours workday in 1 condition (total 12 times).	The dilation and contraction of the pupils of the test subjects' eyes will be recorded using a special camera (Gazepoint, Vancouver, Canada), which will be placed under the computer screen, in front of the subject.	ClinicalTrials.gov
Primary	The psycho-emotional state: Dundee Stress State Questionnaire (DSSQ)	Before and 8 times during simulated 8 hours workday in 1 condition (total 27 times).	The psycho-emotional state of the subjects will be assessed using the Dundee Stress State Questionnaire (DSSQ). The DSSQ questionnaire will be used to assess the subjects' motivation in relation to the content of the task, performing a cognitive test battery during the mental work day. 15 questions will be used, e.g.: "the content of the task was interesting", "I wanted to do the task well compared to others", etc. The subject will have to mark the corresponding answers to each question, where 4 (strongly), 3 (very), 2 (a little), 1 (a little), 0 (not at all).	ClinicalTrials.gov
Primary	The psycho-emotional state: the VAS scale	Before and 8 times during simulated 8 hours workday in 1 condition (total 27 times).	Motivation, mental fatigue and mind wondering will be assessed using a visual analogue scale (VAS). Subjects will mark their feelings on a 10 centimetres horizontal line from 0 ("completely unmotivated"; "not mentally tired"; "no mind wandering") to 100 ("maximum motivated"; "maximum mental fatigue"; "maximum mind wandering").	ClinicalTrials.gov
Primary	The psycho-emotional state: Stanford sleepiness scale.	Before and 8 times during simulated 8 hours workday in 1 condition (total 27 times).	The Stanford Sleepiness Scale will be used to assess subjects' sleepiness. On this scale, subjects will mark their level of sleepiness from 1 "I feel active, efficient, lively, alert or awake" to 7 "I can no longer fight sleep, I will fall asleep quickly; thoughts are like dreams".	ClinicalTrials.gov
Primary	Measurement of maximal aerobic capacity	Before.	The maximal aerobic capacity of the subjects will be measured in order to determine the average aerobic load, which will be applied in the study condition "aerobic activity ". The subjects will perform a consistently increasing load until complete fatigue on a bicycle ergometer (Lode B.V., Excalibur Sport, Groningen, Netherlands). Throughout the test, subjects will have their heart rate monitored using a chest strap heart rate monitor (Polar H10, Kempele, Finland). A spirometry system (Metalyzer 3B, Cortex, Leipzig, Germany) will be used to measure oxygen uptake (VO2). VO2max (maximum oxygen uptake) will be considered the highest oxygen uptake during any 15 s of exercise.	ClinicalTrials.gov
Primary	Sleep quality assessment	3 days before each condition and during testings.	Sleep (hours of total sleep and sleep stages) will be monitored using a Garmin wrist-worn watch (Vivo fit 4, UK).	ClinicalTrials.gov
Primary	Physical activity assessment	3 days before each condition and during testings.	Physical activity (steps per day) will be monitored using a Garmin wrist-worn watch (Vivo fit 4, UK).	ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as	Source

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units	Source

Participant flow 0

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants	Units counted	Source

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events	Source

Adverse event totals 0

The totals the trial posted for each group.

Total	Group	Affected	At risk	Source

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source

Tests 1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Stroop Color-Word Test	Primary outcome	ConductCognition

Source 5

Field	Value	Source
Release	trials-2026-11-12-0.4.0	ClinicalTrials.gov
Release manifest SHA-256	0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4	ClinicalTrials.gov
Registry capture	2026-11-12	ClinicalTrials.gov
Results copy, AACT	2026-03-23	ClinicalTrials.gov
NIH clinical studies file	2026-11-13	ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)